Published in Medical Letter on the CDC and FDA, September 26th, 2004
The primary objective of this newly initiated clinical trial is to evaluate whether the 40 mg immediate-release Zegerid (omeprazole) capsules are pharmacokinetically equivalent to 40 mg delayed-release omeprazole capsules with respect to total systemic bioavailability.
The trial will also assess whether Zegerid capsules and the delayed-release...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA